Adult ADHD Self-Report Scale (ASRS v1.1)
18-item self-report screening tool for adult ADHD developed with WHO. Part A (items 1–6) is the validated screener — a positive screen requires ≥4 items shaded in the dark zone. Full 18-item scale assesses full symptom picture.
Score interpretation
ASRS Part A score <4 — ADHD symptoms below screening threshold
→ ADHD unlikely based on screener; if clinical concern persists, complete all 18 items and consider formal neuropsychological assessment
ASRS Part A score ≥4 — positive screen for adult ADHD
→ Full diagnostic evaluation: complete 18-item ASRS; clinical interview (childhood history, functional impairment); exclude mood/anxiety disorders; neuropsychological testing; consider psychiatry referral; NICE guidelines recommend CBT + pharmacotherapy (methylphenidate/lisdexamfetamine) for confirmed ADHD
Interpretation bands for the ASRS ADHD. Apply clinical judgement and local guidance.
References
- Kessler RC et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–256.
Related
Curated clinical cross-links plus same-class fallbacks.
- Lisdexamfetamine · CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)
- Atomoxetine · Selective Noradrenaline Reuptake Inhibitor (SNRI) — ADHD (Non-Stimulant)
- Risperidone (Paediatric) · Atypical Antipsychotic — Autism Spectrum Disorder / Schizophrenia / Tic Disorders
- Carbamazepine (Paediatric) · Antiepileptic — Focal Seizures / Trigeminal Neuralgia / Bipolar Disorder
- Sildenafil (Paediatric — PPHN / PAH) · PDE5 Inhibitor (Paediatric Pulmonary Hypertension)
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.